Compare Equinor ASA (EQNR) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Natera Inc. Common Stock — how do they compare? Equinor ASA trades at $45 (market cap $105.42B), while Natera Inc. Common Stock trades at $394 (market cap $57.03B). The key difference: Equinor ASA is the larger of the two by market cap, and Equinor ASA pays a 3.47% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equinor ASA for 59 Days and Natera Inc. Common Stock for 0 Days on average.
| EQNR | NTRA | |
|---|---|---|
Market Cap | $105.42B | $57.03B |
Volume | 4,977,357 | 1,131,157 |
Sector | Energy | Health |
52-Week High | $45.75 | $425.64 |
52-Week Low | $22.41 | $179.42 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | $114.11B | $56.18B |
Dividend Yield | 3.47% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $45.29, up 3.07% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50 implying significant upside. Recent earnings show a mix of beats and one miss, while fundamentals reveal strong cash flow from operations of $20.0B in 2025 and attractive valuation ratios, including a P/E of 12.2 and EV/EBITDA of 2.47. The company is expanding its LNG portfolio and executing share buybacks, supporting positive sentiment.
The outlook for EQNR is positive, driven by undervaluation relative to analyst targets and strategic growth in LNG and carbon capture. Key risks include volatility in energy prices and execution of expansion plans. Earnings growth and dividend stability remain central to investor appeal, with the stock positioned for potential appreciation if operational targets are met.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
